Salloum Antoine, Koblinski Jenna, Bazzi Nagham, Zeitouni Nathalie C
Dr. Salloum is with the Department of Dermatology at Saint George Hospital University Medical Center in Beirut, Lebanon, and Dermatologic Surgicenter in Philadelphia, Pennsylvania.
Drs. Koblinski and Zeitouni are with the University of Arizona College of Medicine in Phoenix, Arizona.
J Clin Aesthet Dermatol. 2021 Nov;14(11):18-25.
Talimogene laherparepvec (T-VEC) is the first oncolytic virus therapy approved by the United States Food and Drug Administration (in 2015) for the treatment of advanced-stage melanoma. Despite a paucity of Phase III trials for T-VEC as a therapy for non-melanoma cancers, successful off-label use of T-VEC for this purpose has been reported in the literature.
We sought to review the literature describing T-VEC as a treatment for non-melanoma cancer.
Systematic searches of the PubMed literature database and ClinicalTrials.gov website were performed in July 2020, focusing on T-VEC in combination with non-melanoma cancer, including squamous cell carcinoma, Merkel cell carcinoma, sarcoma, cutaneous B-cell lymphoma, and cutaneous T-cell lymphoma. Articles were screened based on their title and abstract.
Nine articles with 87 patients were included. Relevant articles included case reports, case series, and Phase I and Phase II trials. The majority of patients in the studies had refractory cancers or had been heavily pretreated. Overall, T-VEC demonstrated efficacy for non-melanoma cancer, both independently and in combination with biologics.
T-VEC has demonstrated efficacy for non-melanoma cancers. Phase III trials of T-VEC for this indication are warranted to expand its clinical utility.
talimogene laherparepvec（T-VEC）是美国食品药品监督管理局于2015年批准的首个用于治疗晚期黑色素瘤的溶瘤病毒疗法。尽管关于T-VEC治疗非黑色素瘤癌症的III期试验较少，但文献报道了T-VEC在此用途上成功的非标签使用情况。
我们试图回顾描述T-VEC治疗非黑色素瘤癌症的文献。
2020年7月对PubMed文献数据库和ClinicalTrials.gov网站进行了系统检索，重点关注T-VEC与非黑色素瘤癌症（包括鳞状细胞癌、默克尔细胞癌、肉瘤、皮肤B细胞淋巴瘤和皮肤T细胞淋巴瘤）的联合应用。根据文章标题和摘要进行筛选。
纳入了9篇文章，共87例患者。相关文章包括病例报告、病例系列以及I期和II期试验。研究中的大多数患者患有难治性癌症或接受过大量预处理。总体而言，T-VEC在非黑色素瘤癌症中显示出疗效，无论是单独使用还是与生物制剂联合使用。
T-VEC已在非黑色素瘤癌症中显示出疗效。有必要开展T-VEC针对该适应症的III期试验以扩大其临床应用。
